In 2021, the results of a clinical trial (NCT04326023) examining the efficiency of PARP inhibitors, including olaparib, rucaparib, niraparib, talazoparib and veliparib, in 178 patients with MDS and AML were reported [100]. The gene discussed is PARP1; the disease is myelodysplastic syndrome.